MedTrace Logo

Dietary Fructose on Microbiota and Hepatosteatosis

NCT04898621 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-06-07

No results posted yet for this study

Summary

The consumption of sugar-sweetened beverages (SSB) has increased steadily over the past decades, resulting in the dramatic increase of fructose intake as it is one of the main ingredients of artificial sweeteners. Recently, large epidemiological studies have documented the association between a high-fructose-diet and hepatic steatosis, and other metabolic disorders. So it is interesting for scientists to explore the underlying mechanism. This study aims to investigate the effect of dietary fructose and gut microbiota and the hepatosteatosis in healthy men. Serum and fecal metabolomics will be investigated.

Conditions

  • Hepatic Steatosis
  • Dietary Fructose Exposure

Interventions

DIETARY_SUPPLEMENT

75g fructose solution

Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.

DIETARY_SUPPLEMENT

150g fructose solution

Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Xiaoying Li · Shanghai Zhongshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-08-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04898621 on ClinicalTrials.gov